Tarsus Pharmaceuticals (TARS) said late Wednesday it has priced an upsized underwritten public offering of 2.8 million shares at $44.50 per share for gross proceeds of about $125 million.
Underwriters have been granted a 30-day option to purchase up to 421,348 additional shares.
The offering, which was upsized from the initial $100 million, is set to close Friday.